Rothschild & Co Redburn Raises Lam Research (NASDAQ:LRCX) Price Target to $140.00

Lam Research (NASDAQ:LRCX) had its price objective lifted by analysts at Rothschild & Co Redburn from $115.00 to $140.00 in a report released on Wednesday,MarketScreener reports. The brokerage presently has a “buy” rating on the semiconductor company’s stock. Rothschild & Co Redburn’s target price would suggest a potential downside of 4.76% from the company’s previous close.

Several other research analysts have also recently issued reports on LRCX. Citigroup increased their price objective on Lam Research from $113.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, September 8th. Erste Group Bank began coverage on Lam Research in a research note on Thursday, August 14th. They issued a “buy” rating on the stock. Summit Insights cut Lam Research from a “buy” rating to a “hold” rating in a research note on Thursday, July 31st. Wells Fargo & Company set a $98.00 price objective on Lam Research and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. Finally, Deutsche Bank Aktiengesellschaft raised Lam Research from a “hold” rating to a “buy” rating and increased their price objective for the stock from $100.00 to $150.00 in a research note on Monday. Twenty-two equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Lam Research currently has a consensus rating of “Moderate Buy” and an average target price of $119.20.

Lam Research Trading Up 2.9%

LRCX opened at $146.99 on Wednesday. The stock has a market cap of $185.36 billion, a price-to-earnings ratio of 35.33, a P/E/G ratio of 1.74 and a beta of 1.83. The stock’s 50 day moving average price is $109.49 and its 200-day moving average price is $91.80. Lam Research has a one year low of $56.32 and a one year high of $147.35. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.55 and a current ratio of 2.21.

Lam Research (NASDAQ:LRCX) last released its earnings results on Wednesday, July 30th. The semiconductor company reported $1.33 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.12. The firm had revenue of $5.17 billion for the quarter, compared to analysts’ expectations of $4.99 billion. Lam Research had a return on equity of 58.17% and a net margin of 29.07%.The company’s quarterly revenue was up 33.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.03 earnings per share. Lam Research has set its Q1 2026 guidance at 1.100-1.300 EPS. On average, equities analysts forecast that Lam Research will post 3.71 EPS for the current year.

Institutional Investors Weigh In On Lam Research

Several institutional investors have recently added to or reduced their stakes in LRCX. IMG Wealth Management Inc. acquired a new position in shares of Lam Research during the second quarter valued at about $26,000. Howard Hughes Medical Institute acquired a new position in shares of Lam Research during the second quarter valued at about $27,000. Strategic Wealth Investment Group LLC acquired a new position in shares of Lam Research during the second quarter valued at about $29,000. Delos Wealth Advisors LLC acquired a new position in shares of Lam Research during the second quarter valued at about $30,000. Finally, REAP Financial Group LLC acquired a new position in shares of Lam Research during the second quarter valued at about $31,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.